Intellia Therapeutics is confronting a major survival challenge after its CRISPR gene-editing treatment was linked to severe, potentially fatal liver toxicity, raising serious safety concerns.
Back
Intellia Therapeutics is confronting a major survival challenge after its CRISPR gene-editing treatment was linked to severe, potentially fatal liver toxicity, raising serious safety concerns.